(Leukemia) Effectiveness of Ibrutinib + Venetoclax?
Medical Supporter — Information Notice
This article is a summary of international medical information and is not medical advice; it cannot replace the diagnosis or treatment plan of your attending physician. The medical technologies, drug information and clinical data presented here are compiled from public literature and official statements of major Japanese medical institutions; the applicability and outcome of any therapy vary with each patient and must be assessed individually by a qualified physician.
Both BTK inhibitor Ibrutinib monotherapy and combined BCL2 inhibitor Venetoclax + other treatments, without appropriate selection based on patient biological characteristics, may lead to unnecessary medication and economic losses. This trial evaluated the combination of Ibrutinib + Venetoclax to determine whether this targeted therapy combination could improve outcomes in patients with chronic lymphocytic leukemia compared to standard treatment options.
Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Considering medical care in Japan? Need information and support?
We help you organize the information needed for medical travel to Japan, liaise with Japanese medical institutions, and arrange a second-opinion consultation.The first consultation is free; an advisor will help you clarify the next steps.
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5